Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
PetVivo Holdings, Inc.
- Market Cap
- Unavailable
- Price
- $0.70
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 30.6K
About
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
Quick stats
Shares outstanding—
Computed float16.1M
Float / sharesUnknown
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001512922
Websitehttps://www.petvivo.com
AI Summary
AI-generated1/28
minorbullishother
PETVIVO HOLDINGS ANNOUNCES NAME CHANGE OF HUMAN SUBSIDIARY TO SOMATRIX TECHNOLOGIES, INC. AND EXPANDS FOCUS ON HUMAN HEALTH INNOVATION
PetVivo Holdings rebranded its human health subsidiary from Cosmeta Corp. to Somatrix Technologies, Inc., marking a strategic expansion to leverage its biomaterial platform for human health applications.
The company will maintain separate focuses, with Somatrix targeting human therapeutic areas and PetVivo Animal Health continuing its veterinary commercialization efforts.
PetVivo holds a portfolio of twelve issued and pending patents and six trade secrets, which it intends to utilize across both the new human initiatives and its existing veterinary product pipeline.
Red flags
- Human health expansion is currently pre-revenue and relies on R&D subject to regulatory requirements
- No specific clinical data or timelines provided for Somatrix development programs